Latest News

Mecasermin treatment for Rett Syndrome is safe, well-tolerated

A Phase 1 clinical trial using mecasermin [recombinant human insulin-like growth factor 1 (IGF-1)] has been completed for Rett Syndrome research, showing proof-of-principle that treatments like IGF-1 which are based on the neurobiology of Rett syndrome, are possible.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Severing nerves may shrink stomach cancers: Botox injections slow growth of stomach tumors in mice

  • Maturing brain flips function of amygdala in regulating stress hormones

  • Many solve civil justice problems on their own, rarely involving attorneys, says study

  • Zoning regulations impact where marijuana dispensaries can locate

  • Hatha yoga boosts brain function in older adults, study suggests

  • Rheumatologic diseases like lupus can initially look like neurological disorders

  • Are children who play violent video games at greater risk for depression?

  • Fighting unfairness: Children have advanced ideas about fairness

  • Studies promoting use of antidepressants for postoperative pain may be premature, review finds

  • Dyslexia: Balanced view needed on expensive lenses to improve reading

  •